indivior pharmaceutical | Indivior | Global Pharmaceutical Company

Keyword	CPC	PCC	Volume	Score	Length of keyword
indivior pharmaceutical	0.9	0.8	8950	2	23
indivior	0.49	0.2	2839	62	8
pharmaceutical	0.38	0.1	6625	39	14

Keyword	CPC	PCC	Volume	Score
indivior pharmaceutical	0.71	0.7	6290	22
indivior pharmaceuticals usa	1.11	0.5	9398	84
indivior pharmaceuticals products	1.99	0.9	6216	7
indivior pharmaceuticals careers	0.03	0.3	2318	51
indivior pharmaceutical jobs	0.25	0.7	8515	65
indivior pharmaceutical stock	1.51	0.8	3069	38
indivior pharmaceutical richmond va	1.68	0.4	6255	83
indivior inc pharmaceuticals usa	1.06	0.1	8795	76

Search Results related to indivior pharmaceutical on Search Engine

Indivior | Global Pharmaceutical Company
indivior.com

https://www.indivior.com/

WebLatest Results. March 13 2024. Annual Report and Accounts 2023. Read more. Share price. Nasdaq: INDV 18.52 USD. -0.24. 04:00 PM. LON: INDV 1,514.00 GBp. -10.00. 04:35 PM. Read more. Indivior is working to change patients lives by developing medicines to treat addiction and serious mental illnesses.

DA: 49 PA: 29 MOZ Rank: 27

Indivior | About Us
indivior.com

https://www.indivior.com/en/about-us

WebIndivior is a global pharmaceutical company working to help change patients’ lives by pioneering life-transforming treatment for substance use disorders and other serious mental illnesses. Our Approach. Our leadership. Learn about Indivior’s Board of Directors and Executive Committee. Read more. Corporate Governance.

DA: 61 PA: 96 MOZ Rank: 3

Indivior | Products
indivior.com

https://www.indivior.com/en/products

WebProducts. Our Prescription Medicines. Our portfolio of products is available in 37 countries. Within these countries, product availability may differ in terms of dosage form, strength and indication. Country specific product and prescribing information available upon request.

DA: 72 PA: 74 MOZ Rank: 87

Indivior Announces U.S. Food and Drug Administration Approval …
prnewswire.com

https://www.prnewswire.com/news-releases/indivior-announces-us-food-and-drug-administration-approval-of-opvee-nalmefene-nasal-spray-an-opioid-overdose-rescue-medicine-for-natural-and-synthetic-opioids-like-fentanyl-301831447.html

WebRICHMOND, Va., May 22, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced that the U.S. Food and Drug Administration (FDA) approved OPVEE ® (nalmefene) nasal spray for the emergency...

DA: 83 PA: 37 MOZ Rank: 30

Indivior - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Indivior

WebIn November 2022, it was announced Indivior had acquired the Santa Monica-headquartered, NASDAQ-listed biopharmaceutical company, Opiant. In July 2023 Indivior paid $20.4 million to C4X Discovery for the full rights to the orexin-1 receptor antagonist being developed for substance use disorder.

DA: 57 PA: 21 MOZ Rank: 54

Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.
prnewswire.com

https://www.prnewswire.com/news-releases/indivior-completes-acquisition-of-opiant-pharmaceuticals-inc-301761055.html

WebMar 02, 2023, 10:14 ET. Share this article. Combination Strengthens Indivior's Addiction Treatment and Science Portfolio. RICHMOND, Va., March 2, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV)...

DA: 79 PA: 97 MOZ Rank: 28

Indivior | LinkedIn
linkedin.com

https://www.linkedin.com/company/indivior

WebIndivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorder and serious mental illnesses. Our vision is that all...

DA: 61 PA: 5 MOZ Rank: 55

Indivior | Indivior PLC – OPVEE FDA Approval - Opiant
opiant.com

https://www.opiant.com/en/media/press-releases/indiviorplc-opvee-approval

WebMay 22, 2023 · Indivior | Indivior PLC – OPVEE FDA Approval. Press Releases. Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl. May 22 2023.

DA: 16 PA: 22 MOZ Rank: 100

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals
yahoo.com

https://finance.yahoo.com/news/indivior-enters-exclusive-licensing-agreement-202000331.html

WebRICHMOND, Va., Oct. 11, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, today announced that it has gained exclusive global rights to develop,...

DA: 12 PA: 74 MOZ Rank: 62

Indivior agrees to acquire Opiant Pharmaceuticals for $145m
pharmaceutical-technology.com

https://www.pharmaceutical-technology.com/news/indivior-to-acquire-opiant/

WebNov 15, 2022 · Indivior has signed a definitive agreement to acquire all outstanding shares of Opiant Pharmaceuticals for an upfront payment of $20 for each share in cash or a deal totalling nearly $145m. In addition to the upfront consideration, Opiant is entitled to get up to $8 for a share in contingent value rights (CVRs).

DA: 57 PA: 65 MOZ Rank: 49